Literature DB >> 31991250

Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone.

Kathryn M Thrailkill1, R Clay Bunn2, Sasidhar Uppuganti3, Philip Ray2, Kate Garrett3, Iuliana Popescu2, Jacquelyn S Pennings4, John L Fowlkes2, Jeffry S Nyman3.   

Abstract

Selective sodium-dependent glucose co-transporter 2 inhibitors (SGLT2Is) are oral hypoglycemic medications utilized increasingly in the medical management of hyperglycemia among persons with type 2 diabetes (T2D). Despite favorable effects on cardiovascular events, specific SGLT2Is have been associated with an increased risk for atypical fracture and amputation in subgroups of the T2D population, a population that already has a higher risk for typical fragility fractures than the general population. To better understand the effect of SGLT2 blockade on skeletal integrity, independent of diabetes and its co-morbidities, we utilized the "Jimbee" mouse model of slc5a2 gene mutation to investigate the impact of lifelong SGLT2 loss-of-function on metabolic and skeletal phenotype. Jimbee mice maintained normal glucose homeostasis, but exhibited chronic polyuria, glucosuria and hypercalciuria. The Jimbee mutation negatively impacted appendicular growth of the femur and resulted in lower tissue mineral density of both cortical and trabecular bone of the femur mid-shaft and distal femur metaphysis, respectively. Several components of the Jimbee phenotype were characteristic only of male mice compared with female mice, including reductions: in body weight; in cortical area of the mid-shaft; and in trabecular thickness within the metaphysis. Despite these decrements, the strength of femur diaphysis in bending (cortical bone), which increased with age, and the strength of L6 vertebra in compression (primarily trabecular bone), which decreased with age, were not affected by the mutation. Moreover, the age-related decline in bone toughness was less for Jimbee mice, compared with control mice, such that by 49-50 weeks of age, Jimbee mice had significantly tougher femurs in bending than C57BL/6J mice. These results suggest that chronic blockade of SGLT2 in this model reduces the mineralization of bone but does not reduce its fracture resistance.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone microarchitecture; Canagliflozin; Cortical bone; Fracture; Jimbee mouse; Proximal tubule; Trabecular bone

Mesh:

Substances:

Year:  2020        PMID: 31991250      PMCID: PMC7059549          DOI: 10.1016/j.bone.2020.115254

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  43 in total

1.  Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses.

Authors:  Franz Faul; Edgar Erdfelder; Axel Buchner; Albert-Georg Lang
Journal:  Behav Res Methods       Date:  2009-11

2.  The effects of ageing and changes in mineral content in degrading the toughness of human femora.

Authors:  J D Currey; K Brear; P Zioupos
Journal:  J Biomech       Date:  1996-02       Impact factor: 2.712

3.  Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences.

Authors:  Ivan Sabolic; Ivana Vrhovac; Daniela Balen Eror; Maria Gerasimova; Michael Rose; Davorka Breljak; Marija Ljubojevic; Hrvoje Brzica; Anne Sebastiani; Serge C Thal; Christoph Sauvant; Helmut Kipp; Volker Vallon; Hermann Koepsell
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-18       Impact factor: 4.249

Review 4.  Bone disease in diabetes.

Authors:  M Luisa Isidro; Belén Ruano
Journal:  Curr Diabetes Rev       Date:  2010-05

5.  Low bone toughness in the TallyHO model of juvenile type 2 diabetes does not worsen with age.

Authors:  Amy Creecy; Sasidhar Uppuganti; Mustafa Unal; R Clay Bunn; Paul Voziyan; Jeffry S Nyman
Journal:  Bone       Date:  2018-02-10       Impact factor: 4.398

6.  Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.

Authors:  Sven Kohler; Afshin Salsali; Stefan Hantel; Stefan Kaspers; Hans J Woerle; Gabriel Kim; Uli C Broedl
Journal:  Clin Ther       Date:  2016-04-13       Impact factor: 3.393

7.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

8.  Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.

Authors:  Julio Rosenstock; Jan Marquard; Lori M Laffel; Dietmar Neubacher; Stefan Kaspers; David Z Cherney; Bernard Zinman; Jay S Skyler; Jyothis George; Nima Soleymanlou; Bruce A Perkins
Journal:  Diabetes Care       Date:  2018-10-04       Impact factor: 19.112

9.  Hypercalciuria is a common and important finding in postmenopausal women with osteoporosis.

Authors:  Sandro Giannini; Martino Nobile; Luca Dalle Carbonare; Maria Giuseppina Lodetti; Stefania Sella; Gabriele Vittadello; Nadia Minicuci; Gaetano Crepaldi
Journal:  Eur J Endocrinol       Date:  2003-09       Impact factor: 6.664

10.  Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.

Authors:  Xiaoling Cai; Liwei Ji; Yifei Chen; Wenjia Yang; Lingli Zhou; Xueyao Han; Simin Zhang; Linong Ji
Journal:  J Diabetes Investig       Date:  2017-03-23       Impact factor: 4.232

View more
  3 in total

1.  Impact of an SGLT2-loss of function mutation on renal architecture, histology, and glucose homeostasis.

Authors:  Corey B Hughes; George M Mussman; Phil Ray; Robert C Bunn; Virgilius Cornea; Kathryn M Thrailkill; John L Fowlkes; Iuliana Popescu
Journal:  Cell Tissue Res       Date:  2021-01-06       Impact factor: 5.249

2.  Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits.

Authors:  Kathryn M Thrailkill; R Clay Bunn; Sasidhar Uppuganti; Philip Ray; Iuliana Popescu; Evangelia Kalaitzoglou; John L Fowlkes; Jeffry S Nyman
Journal:  Bone       Date:  2020-09-02       Impact factor: 4.398

Review 3.  Tubular effects of sodium-glucose cotransporter 2 inhibitors: intended and unintended consequences.

Authors:  Jessica A Dominguez Rieg; Jianxiang Xue; Timo Rieg
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-09       Impact factor: 2.894

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.